# Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

> **NCT01468818** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Melanoma
- Skin Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Young Tumor Infiltrating Lymphocytes (TIL)

## Key facts

- **NCT ID:** NCT01468818
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Study was closed prematurely due to slow and insufficient accrual.
- **Last updated:** 2016-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01468818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01468818, "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01468818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*